This study is testing a combination of three drugs – Gemcitabine, Mitomycin C, and Thalidomide – for people with advanced solid tumors (cancers that form in solid organs). You might be able to join if you are at least 18 years old, have a solid tumor that has spread or is advanced, and have already received some treatment. The study is looking to see how long people live without their cancer getting worse (Progression Free Survival) over 12 months. The current status of this study is unclear, but it plans to enroll up to 60 participants.

Study design

This is an open-label Phase II study, meaning both you and your doctors will know which treatments you are receiving. It plans to enroll 40-60 participants.

What's involved

You would receive Gemcitabine intravenously (into a vein) on days 1, 8, and 15, Mitomycin C intravenously every 6 weeks, and Thalidomide by mouth daily for 15 days. You would have CT scans or MRIs every 6 weeks for the first 6 months, and then every 12 weeks after that, for up to one year.

Compensation

Not stated in the trial record.

Follow-up

Your disease progression will be monitored for up to one year of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.